In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 409-417

  Sun, Shujuan ^a   Li, Yan ^a   Guo, Qiongjie ^b   Shi, Changwen ^a   Yu, Jinlong ^b   Ma, Lin ^b  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS[2 METHOXY 4 NITRO 5 [(SULFENYLAMINO)CARBONYL] 2H TETRAZOLIUM]; CALCINEURIN INHIBITOR; CARBONYL DERIVATIVE; FLUCONAZOLE; ITRACONAZOLE; NITRO DERIVATIVE; PYRROLE DERIVATIVE; TACROLIMUS; TETRAZOLIUM; UNCLASSIFIED DRUG; VORICONAZOLE;

ANALYTIC METHOD; ARTICLE; CANDIDA ALBICANS; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FRACTIONAL INHIBITORY CONCENTRATION INDEX; FUNGAL STRAIN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

AZOLES; CANDIDA ALBICANS; COLONY COUNT, MICROBIAL; COLORIMETRY; CULTURE MEDIA; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; DRUG SYNERGISM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; SPECTROPHOTOMETRY; TACROLIMUS;

EID: 38649102505     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01070-07     Document Type: Article

References (48)

1. Afeltra, J., R. G. Vitale, J. W. Mouton, and P. E. Verweij. 2004. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob. Agents Chemother. 48:1335-1343.
2. Barchiesi, F., L. F. Di Francesco, P. Compagnucci, D. Arzeni, A. Giacometti, and C. Scalise. 1998. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. J. Antimicrob. Chemother. 41:59-65.
3. Baumgartner, C., A. Freydiere, and Y. Gile. 1996. Direct identification and recognition of yeast species from clinical material by using Albicans ID and CHROMagar Candida plates. J. Clin. Microbiol. 34:454-456.
4. Berenbaum, M. C. 1978. A method for testing for synergy with any number of agents. J. Infect. Dis. 137:122-130.
5. Berenbaum, M. C. 1989. What is synergy? Pharmacol. Rev. 41:93-141.
6. Cardenas, M. E., M. C. Cruz, M. Del Poeta, N. Chung, J. R. Perfect, and J. Heitman. 1999. Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin. Microbiol. Rev. 12:583-611.
7. Cruz, M. C., M. Del Poeta, P. Wang, R. Wenger, G. Zenke, V. F. Quesniaux, N. R. Movva, J. R. Perfect, M. E. Cardenas, and J. Heitman. 2000. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob. Agents Chemother. 44:143-149.
8. 1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:739-746.
9. Denning, D. W., G. G. Baily, and S. V. Hood. 1997. Azole resistance in Candida. Eur. J. Clin. Microbiol. Infect. Dis. 16:261-280.
10. Ernst, E. J., E. E. Roling, C. R. Petzold, D. J. Keele, and M. E. Klepser. 2002. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. 46:3846-3853.
11. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, A. Fothergill, M. A. Pfaller, M. Rinaldi, J. L. Rodriguez-Tudela, and P. E. Verweij. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J. Clin. Microbiol. 43:4535-4540.
12. Fricker-Hidalgo, H., O. Vandapel, M. A. Duchesne, M. A. Mazoyer, D. Monget, B. Lardy, B. Lebeau, J. Freney, P. Ambroise-Thomas, and R. Grillot. 1996. Comparison of the new API Candida system to the ID 32C system for the identification of clinically important yeast species. J. Clin. Microbiol. 34:1846-1848.
13. Graybill, J. R. 1997. Editorial response: can we agree on the treatment of candidiasis? Clin. Infect. Dis. 25:60-62.
14. Greco, W. R., G. Bravo, and J. C. Parsons. 1995. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47:331-385.
15. Hibberd, P. L., and R. H. Rubin. 1994. Clinical aspects of fungal infection in organ transplant recipients. Clin. Infect. Dis. 19(Suppl.):S33-S40.
16. Klepser, M. E., E. J. Ernst, R. E. Lewis, M. E. Ernst, and M. A. Pfaller. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42:1207-1212.
17. Kuhn, D. M., J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect. Immun. 70:878-888.
18. Lewis, R. E., D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser. 2002. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemother. 49:345-351.
19. Liu, J., J. D. Farmer, Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber. 1991. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815.
20. Maesaki, S., P. Marichal, M. A. Hossain, D. Sanlard, H. V. Bossche, and S. Kohno. 1998. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J. Antimicrob. Chemother. 42:747-753.
21. Marchetti, O., P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44:2373-2381.
22. Meletiadis, J., J. F. Meis, J. W. Mouton, J. P. Donnelly, and P. E. Verweij. 2000. Comparison of NCCLS and 3-(4,5-dimethyl-2-thiazyl)-2,5- diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method. J. Clin. Microbiol. 38:2949-2954.
23. Meletiadis, J., J. W. Mouton, J. F. Meis, B. A. Bouman, P. J. Donnelly, P. E. Verweij, and EUROFUNG Network. 2001. Comparison of spectrophotometric and visual reading of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2,3-bis {2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium hydroxide}, for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:4256-4263.
24. Meletiadis, J., J. W. Mouton, J. F. G. M. Meis, and P. E. Verweij. 2003. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 47:106-117.
25. Moody, J. A. 1992. Synergism testing: broth microdilution checkerboard and broth macrodilution methods, p. 1-28. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. American Society for Microbiology, Washington, DC.
26. Mukherjee, P. K., D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194.
27. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
28. Nguyen, M. H., F. Barchiesi, D. A. McGough, V. L. Yu, and M. G. Rinaldi. 1995. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. Antimicrob. Agents Chemother. 39:1691-1695.
29. Odds, F. C. 1996. Resistance of clinically important yeasts to antifungal agents. Int. J. Antimicrob. Agents 6:145-147.
30. Odds, F. C. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1.
31. Odom, A., M. Del Poeta, J. R. Perfect, and J. Heitman. 1997. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother. 41:156-161.
32. Odom, A., S. Muir, E. Lim, D. L. Toffaletti, J. R. Perfect, and J. Heitman. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16:2576-2589.
33. Onyewu, C., J. R. Blankenship, M. Del Poeta, and J. Heitman. 2003. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47:956-964.
34. Paya, C. V. 1993. Fungal infections in solid-organ transplantation. Clin. Infect. Dis. 16:677-688.
35. Pfaller, M. A., A. Houston, and S. Coffman. 1996. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 34:58-61.
36. Pfaller, M. A., D. J. Sheehan, and J. H. Rex. 2004. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280.
37. Polak, A. 1999. The past, present and future of antimycotic combination therapy. Mycoses 42:355-370.
38. Prichard, M. N., and C. Shipman, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14:181-205.
39. Prichard, M. N., L. E. Prichard, and C. Shipman, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob. Agents Chemother. 37:540-545.
40. Prichard, M. N., L. E. Prichard, W. A. Baguley, M. R. Nassiri, and C. Shipman, Jr. 1991. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine. Antimicrob. Agents Chemother. 35:1060-1065.
41. Ramage, G., K. V. Walle, B. L. Wickes, and J. L. López- Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
42. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, and C. D. Webb. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
43. Sahuquillo Arce, J. M., E. Colombo Gainza, A. Gil Brusola, R. Ortiz Estevez, E. Canton, and M. Gobernado. 2006. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev. Esp. Quimioter. 19:252-257.
44. Sanglard, D., F. Ischer, O. Marchetti, J. Entenza, and J. Bille. 2003. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol. 48:959-976.
45. Steinbach, W. J., W. A. Schell, J. R. Blankenship, C. Onyewu, J. Heitman, and J. R. Perfect. 2004. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus. Antimicrob. Agents Chemother. 48:1664-1669.
46. Steinbach, W. J., N. Singh, J. L. Miller, D. K. Benjamin, Jr., W. A. Schell, J. Heitman, and J. R. Perfect. 2004. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients. Antimicrob. Agents Chemother. 48:4922-4925.
47. Te Dorsthorst, D. T. A., P. E. Verweij, J. F. G. M. Meis, N. C. Punt, and J. W. Mouton. 2004. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob. Agents Chemother. 48:2007-2013.
48. Te Dorsthorst, D. T., P. E. Verweij, J. Meletiadis, M. Bergervoet, N. C. Punt, J. F. Meis, and J. W. Mouton. 2002. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob. Agents Chemother. 46:2982-2989.